Silexion Therapeutics Shares Set to Reverse Split on Wednesday, November 11th (NASDAQ:SLXN)

Silexion Therapeutics Corp (NASDAQ:SLXN)’s stock is going to reverse split on the morning of Wednesday, November 11th. The 1-24 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Tuesday, November 10th.

Silexion Therapeutics Stock Performance

Shares of NASDAQ SLXN traded down $0.01 during mid-day trading on Tuesday, reaching $0.11. 635,055 shares of the company traded hands, compared to its average volume of 3,242,905. The stock has a market cap of $605,484.00, a PE ratio of -0.00 and a beta of -0.30. The company’s fifty day moving average is $0.25 and its two-hundred day moving average is $6.16. Silexion Therapeutics has a fifty-two week low of $0.11 and a fifty-two week high of $32.38.

Silexion Therapeutics (NASDAQ:SLXN) last posted its quarterly earnings results on Saturday, August 15th. The company reported ($5.17) EPS for the quarter, beating the consensus estimate of ($21.20) by $16.03. Research analysts forecast that Silexion Therapeutics will post -4.70 earnings per share for the current year.

Analysts Set New Price Targets

Several analysts recently weighed in on SLXN shares. Maxim Group downgraded Silexion Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, July 29th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Silexion Therapeutics in a research report on Friday, September 11th. One research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold”.

Silexion Therapeutics Company Profile

Silexion Therapeutics Ltd. (NASDAQ: SLXN) is an Israel-based clinical-stage biotechnology company developing RNA-based medicines for the treatment of solid tumors driven by mutations in the KRAS oncogene. The company’s technology is designed to selectively silence cancer-causing KRAS mutations while limiting exposure to healthy tissue. Silexion’s lead program, siG12D-LODER, is an investigational RNA interference therapy targeting the KRAS G12D mutation, which is frequently found in pancreatic and other difficult-to-treat cancers.